These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 23094831)

  • 1. Clinical potential of VIP by modified pharmaco-kinetics and delivery mechanisms.
    Burian B; Ortner A; Prassl R; Zimmer A; Mosgoeller W
    Endocr Metab Immune Disord Drug Targets; 2012 Dec; 12(4):344-50. PubMed ID: 23094831
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Depot formulation of vasoactive intestinal peptide by protamine-based biodegradable nanoparticles.
    Wernig K; Griesbacher M; Andreae F; Hajos F; Wagner J; Mosgoeller W; Zimmer A
    J Control Release; 2008 Sep; 130(2):192-8. PubMed ID: 18601963
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhalable liposomal formulation for vasoactive intestinal peptide.
    Hajos F; Stark B; Hensler S; Prassl R; Mosgoeller W
    Int J Pharm; 2008 Jun; 357(1-2):286-94. PubMed ID: 18328650
    [TBL] [Abstract][Full Text] [Related]  

  • 4. VPAC receptor mediated tumor cell targeting by protamine based nanoparticles.
    Ortner A; Wernig K; Kaisler R; Edetsberger M; Hajos F; Köhler G; Mosgoeller W; Zimmer A
    J Drug Target; 2010 Jul; 18(6):457-67. PubMed ID: 20050817
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bioactive analogues and drug delivery systems of vasoactive intestinal peptide (VIP) for the treatment of asthma/COPD.
    Onoue S; Yamada S; Yajima T
    Peptides; 2007 Sep; 28(9):1640-50. PubMed ID: 17537541
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of dry powder inhalation system of novel vasoactive intestinal peptide (VIP) analogue for pulmonary administration.
    Ohmori Y; Onoue S; Endo K; Matsumoto A; Uchida S; Yamada S
    Life Sci; 2006 Jun; 79(2):138-43. PubMed ID: 16458931
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Liposomal vasoactive intestinal peptide for lung application: protection from proteolytic degradation.
    Stark B; Andreae F; Mosgoeller W; Edetsberger M; Gaubitzer E; Koehler G; Prassl R
    Eur J Pharm Biopharm; 2008 Sep; 70(1):153-64. PubMed ID: 18555674
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical endocrinology and metabolism. Potential clinical applications of vasoactive intestinal peptide: a selected update.
    Gozes I; Furman S
    Best Pract Res Clin Endocrinol Metab; 2004 Dec; 18(4):623-40. PubMed ID: 15533779
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prospect of vasoactive intestinal peptide therapy for COPD/PAH and asthma: a review.
    Wu D; Lee D; Sung YK
    Respir Res; 2011 Apr; 12(1):45. PubMed ID: 21477377
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel concepts of neuropeptide-based drug therapy: vasoactive intestinal polypeptide and its receptors.
    Groneberg DA; Rabe KF; Fischer A
    Eur J Pharmacol; 2006 Mar; 533(1-3):182-94. PubMed ID: 16473346
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapeutic potential of vasoactive intestinal peptide and its receptors in neurological disorders.
    White CM; Ji S; Cai H; Maudsley S; Martin B
    CNS Neurol Disord Drug Targets; 2010 Nov; 9(5):661-6. PubMed ID: 20632962
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Formulation design and in vivo evaluation of dry powder inhalation system of new vasoactive intestinal peptide derivative ([R(15, 20, 21), L(17), A(24,25), des-N(28)]-VIP-GRR) in experimental asthma/COPD model rats.
    Onoue S; Aoki Y; Matsui T; Kojo Y; Misaka S; Mizumoto T; Yamada S
    Int J Pharm; 2011 May; 410(1-2):54-60. PubMed ID: 21419198
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vasoactive intestinal peptide (VIP) stimulates cortisol secretion from the H295 human adrenocortical tumour cell line via VPAC1 receptors.
    Nicol MR; Cobb VJ; Williams BC; Morley SD; Walker SW; Mason JI
    J Mol Endocrinol; 2004 Jun; 32(3):869-77. PubMed ID: 15171718
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunocytochemical identification of VPAC1, VPAC2, and PAC1 receptors in normal and neoplastic human tissues with subtype-specific antibodies.
    Schulz S; Röcken C; Mawrin C; Weise W; Höllt V; Schulz S
    Clin Cancer Res; 2004 Dec; 10(24):8235-42. PubMed ID: 15623599
    [TBL] [Abstract][Full Text] [Related]  

  • 15. VIP enhances synaptic transmission to hippocampal CA1 pyramidal cells through activation of both VPAC1 and VPAC2 receptors.
    Cunha-Reis D; Ribeiro JA; Sebastião AM
    Brain Res; 2005 Jul; 1049(1):52-60. PubMed ID: 15935995
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Protected graft copolymer excipient leads to a higher acute maximum tolerated dose and extends residence time of vasoactive intestinal Peptide significantly better than sterically stabilized micelles.
    Reichstetter S; Castillo GM; Rubinstein I; Nishimoto-Ashfield A; Lai M; Jones CC; Banerjee AA; Lyubimov A; Bloedow DC; Bogdanov A; Bolotin EM
    Pharm Res; 2013 Mar; 30(3):670-82. PubMed ID: 23224976
    [TBL] [Abstract][Full Text] [Related]  

  • 17. VPAC2-R mediates the lipolytic effects of pituitary adenylate cyclase-activating polypeptide/vasoactive intestinal polypeptide in primary rat adipocytes.
    Akesson L; Ahrén B; Edgren G; Degerman E
    Endocrinology; 2005 Feb; 146(2):744-50. PubMed ID: 15514088
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Structure-activity relationship of vasoactive intestinal peptide (VIP): potent agonists and potential clinical applications.
    Onoue S; Misaka S; Yamada S
    Naunyn Schmiedebergs Arch Pharmacol; 2008 Jun; 377(4-6):579-90. PubMed ID: 18172612
    [TBL] [Abstract][Full Text] [Related]  

  • 19. VIP in neurological diseases: more than a neuropeptide.
    Morell M; Souza-Moreira L; González-Rey E
    Endocr Metab Immune Disord Drug Targets; 2012 Dec; 12(4):323-32. PubMed ID: 23094829
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhalable powder formulation of a stabilized vasoactive intestinal peptide (VIP) derivative: anti-inflammatory effect in experimental asthmatic rats.
    Misaka S; Aoki Y; Karaki S; Kuwahara A; Mizumoto T; Onoue S; Yamada S
    Peptides; 2010 Jan; 31(1):72-8. PubMed ID: 19808073
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.